Publications

The publication of research results is a fundamental requirement for improving treatment concepts across the board. iOMEDICO supports the international guidelines on transparency and publication of medical research results.

We regularly present our data at national and international conferences. Our publications appear in scientifically renowned, international journals. Authors are principal investigators, investigators with a high number of participating patients, and iOMEDICO scientists.

TITEL
STUDIE
JAHR
Palbociclib in Combination with either Aromatase Inhibitors or Fulvestrant for Patients with Advanced HR+/HER2- Breast Cancer in Germany: Final Results of the Phase 2 Multicohort INGE-B Trial.

Welslau M, Potthoff K, Zaiss M, Müller L, Brucker C, Salat C, Untch M, Meiler J, Lüftner D, Welt A, Dörfel S, Hagen V, Stein A, Liersch R, Kuhn T, Siebenbach HU, Bing G, Vannier C, Marschner N, Gratzke K.

Oncol Res Treat. 2025;48(1-2):14-25. doi: 10.1159/000542459. Epub 2024 Nov 15. PMID: 39551040; PMCID: PMC11809519.

Abstract

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: - / Journal: Oncology Research and Treatment
INGE-B
2025
Local and central testing for HER2, PD-L1, MSI/MMR, EBV, and CLDN18.2 in advanced gastric cancer: results from the SAPHIR registry.

Potthoff K, Bläker H, Dechow T, Binninger A, Ringwald K, de Buhr R, von der Heyde E, Zahn M.-O., Nusch A, Dörfel S, Schulz H, Haffner I, Höhn A.K., Monecke A, Lorenzen S, Reinacher-Schick A, Jänicke M, Lordick F.

ESMO Real World Data Digit Oncol. 2025 June; Volume 8: 100144. doi:10.1016/j.esmorw.2025.100144. Epub 2025 Apr 29.

Abstract

Indikation: Gastric Cancer, Magenkarzinom / Veranstaltung: - / Journal: ESMO Real World Data and Digital Oncology
SAPHIR
2025
Head-to-head comparison of palbociclib and ribociclib in first-line treatment of HR-positive/HER2-negative metastatic breast cancer with real-world data from the OPAL registry.

Thill M, Zahn MO, Welt A, Nusch A, Zaiss M, Engelken K, Kaltenecker G, Ringwald K, Gratzke K, Dille S, Kruggel L, Jänicke M, Schulz H, Hagen V, Fricker R, Stickeler E, Harbeck N, Wöckel A, Decker T.

Int J Cancer. 2025 May 1;156(9):1770-1782. doi: 10.1002/ijc.35296. Epub 2024 Dec 20. PMID: 39707595; PMCID: PMC11887017.

Abstract

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: - / Journal: International Journal of Cancer
OPAL
2025
Final Results from RIBBIT: A Randomized Phase III Study to Evaluate Efficacy and Quality of Life in Patients with Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer Receiving Ribociclib in Combination with Endocrine Therapy or Chemotherapy with or without Bevacizumab in the First-Line Setting.

Decker T, Zaiss M, Klein D, Hahn A, Hagen V, La Rosée P, Liersch R, Wolff T, Niemeier B, Hillebrand LE, Lennartz C, Chiabudini M, Bengsch F, Indorf M, Marschner N.

Breast Care (Basel). 2024 Feb;19(1):49-61. doi: 10.1159/000535135. Epub 2023 Dec 20.

Abstract

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: - / Journal: Breast Care
RIBBIT
2024
Head-to-head comparison of treatment sequences in advanced pancreatic cancer-Real-world data from the prospective German TPK clinical cohort study.

Marschner N, Haug N, Hegewisch-Becker S, Reiser M, Dörfel S, Lerchenmüller C, Linde H, Wolf T, Hof A, Kaiser-Osterhues A, Potthoff K, Jänicke M; TPK‐Group (Tumour Registry Pancreatic Cancer).

Int J Cancer. 2024 Nov 1;155(9):1629-1640. doi: 10.1002/ijc.35071. Epub 2024 Jul 2.

Abstract

Indikation: Pancreatic Cancer, Pankreaskarzinom / Veranstaltung: - / Journal: International Journal of Cancer
TPK
2024
Patient-reported outcomes in advanced NSCLC before and during the COVID-19 pandemic: Real-world data from the German prospective CRISP Registry (AIO-TRK-0315).

Sebastian M, Eberhardt WEE, von der Heyde E, Dörfel S, Wiegand J, Schiefer C, Losem C, Jänicke M, Fleitz A, Zacharias S, Kaiser-Osterhues A, Hipper A, Dietel C, Bleckmann A, Benkelmann R, Boesche M, Grah C, Müller A, Griesinger F, Thomas M; CRISP Registry Group.

Int J Cancer. 2024 Jun 1;154(11):1967-1978. doi: 10.1002/ijc.34868. Epub 2024 Feb 8.

Abstract

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: - / Journal: International Journal of Cancer
CRISP
2024
Quantifying bias due to missing data in quality of life surveys of advanced-stage cancer patients.

Haug N, Jänicke M, Kasenda B, Marschner N, Frank M.

Qual Life Res 33, 1085–1094 (2024). https://doi.org/10.1007/s11136-023-03588-7

Abstract

Indikation: Breast Cancer, Mammakarzinom, Pancreatic Cancer, Pankreaskarzinom / Veranstaltung: - / Journal: Quality of Life Research
Registerübergreifend
2024
Treatment adherence and effectiveness in patients treated with carfilzomib-based therapy combinations for relapsed/refractory multiple myeloma in Germany: interim results from the non-interventional CARO study.

Knauf W, Uhlig J, von der Heyde E, Losem C, Ammon A, Nusch A, Schlag R, Schulz H, Janssen J, Welslau M, Wilop S, Vannier C, Siebenbach HU, Serrer L, Schuch A, Woerner SM, Engelhardt M, Potthoff K.

Leuk Lymphoma. 2024 Dec 9:1-11. doi: 10.1080/10428194.2024.2436034. Epub ahead of print.

Abstract

Indikation: Haemoblastoma, Hämoblastosen / Veranstaltung: - / Journal: Leukemia and Lymphoma
CARO
2024
Neratinib as Extended Adjuvant Treatment of HER2-Positive/HR-Positive Early Breast Cancer Patients in Germany, Austria, and Switzerland: Interim Results of the Prospective, Observational ELEANOR Study.

Harbeck N, Wrobel D, Zaiss M, Terhaag J, Guth D, Distelrath A, Zahn MO, Wuerstlein R, Lorenz A, Bartsch R, Breitenstein U, Schwitter M, Balic M, Jackisch C, Müller V, Rinnerthaler G, Schmidt M, Zaman K, Schinköthe T, Resch A, Valenti R, Lüftner D.

Breast Care (Basel). 2024 Feb;19(1):1-9. doi: 10.1159/000533657. Epub 2023 Oct 5.

Abstract

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: - / Journal: Breast Care
ELEANOR
2024
First-line maintenance therapy in patients with locally advanced or metastatic urothelial carcinoma in routine care in Germany: Interim results of the prospective CARAT registry

Grünwald V. , Radkowski R. , Müller L. , Ghasemi U. , Goebell P.J. , Deger S. , Andres-Pons A. , Lennartz C. , Jänicke M. , Staehler M. , Gratzke C. , Potthoff K.; 2024

Abstract

Indikation: Urogenital Tumors, Urogenitale Tumore / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
CARAT
2024